Skip to main content

Table 3 Enablers to the discussion of chemoprevention in Family Cancer Centres with supporting quotes

From: Australian clinicians and chemoprevention for women at high familial risk for breast cancer

EVIDENCE Participant No Quote
'Reasonable' evidence in BRCA2 carriers 5C (med oncologist) 17 I think that in a BRCA2 mutation carrier we'll discuss Tamoxifen- I'm a bit more confident about Tamoxifen with a BRCA2, than in a BRCA1.
Side-effects less in younger women 1A (med oncologist) 18 ...side effects at that age [45] are likely be to be small in absolute terms
PRACTICE    
Enroling people on a trial is convenient 1B (med oncologist) 19 When the IBIS I study was recruiting that would be definitely part of my discussion because there was a study that they could participate in to try and get an answer. But then that closed so there's been a window between now and then [-]... There's sort of been a bit of a lull.
Not expensive 5C (med oncologist) 20 identified that not being PBS-listed was not a constraint to prescribing Tamoxifen because it 'is not an expensive drug'
PERCEPTION    
Action of Tamoxifen to reduce risk 'intuitively makes sense' 5C (med oncologist) 21 But intuitively, I can understand how um, Tamoxifen would reduce the risk.
Lack of 'hard data' is not always a barrier to recommending something
5C (med oncologist)
5A (clinical geneticist) 22 5A Breast ultrasound? If you're having MRI? No, but if you aren't having it, then, there's very little hard data...
5C I know there's no hard data but that's never stopped anyone doing anything